Danaher Corporation has partnered with Johns Hopkins University to develop new methods for diagnosing mild traumatic brain injury (TBI). The development process will entail using next-generation immunoassay detection technology provided by Beckman Coulter Diagnostics, a subsidiary of Danaher.

The partnership intends to improve TBI diagnosis using blood-based biomarkers and advanced in vitro diagnostics technology. These techniques may potentially lead to detecting injuries earlier and more accurately to determine better treatment, outcomes, and speedy recovery. The project is part of the Danaher Beacons program, which funds scientific research in collaboration with globally recognized academic researchers.

Beckman Coulter Diagnostics develops novel products aimed at simplifying and automating complex biomedical tests. Its diagnostic systems are used globally in hospitals and critical care environments to assist doctors with disease diagnosis, treatment decisions, and patient monitoring.